I view this as another chance to buy shares while you can still get them.  At only $4, we are barely above where we were back in September 2018.  Some of this is of course because we got diluted over the last few months...the market cap has indeed gone up from C$700 million in early September 2018 to C$800 million today.  In short, although we are done with a Phase 3 trial which took longer than expected (has to be good news right?), and we are no more than 4 months away from top line data, Mr Market has only assigned an insignificant C$100 million incremental value to RVX...and that is before we deduct the cash raised in the last 8 months!

So why are we still at $4?  I think the level of skepticism is simply sky high re RVX.  The market (and particularly weed smoking Canadian institutional investors) have not quite forgotten the Phase 2 yo yo.  As for Big Pharma, there is so much history of getting burned buying Phase 2 companies on the cheap, that they are simply unwilling to do anything till the Phase 3 results are out.

Competition?  I know that some forum writers have said that SGLT2 inhibitors are competition for Apabetalone.  I don't see it that way. Our drug has had zero side effects.  SGLT2?  How about kidney failure, "increase in genital infections, particularly in women"?  For me, Apabetalone will easily take over the market from Jardiance as soon as it is approved.  

Get your RVX while you still can at single digit Canadian dollars!